Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced that shareholders of Medpace Holdings, Inc. (MEDP) who experienced losses have the chance to serve as lead plaintiffs in a securities fraud class action lawsuit. The lawsuit alleges that Medpace and its defendants made materially misleading statements between April 22, 2025, and February 9, 2026, regarding the company's projected book-to-bill ratio and overall business prospects. Investors have until June 8, 2026, to participate as lead plaintiffs.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made materially false and misleading statements regarding its expected book-to-bill ratio, portraying an overly optimistic outlook despite contrary internal information. Investors who suffered losses are encouraged to join the case and have until June 5, 2026, to request to be appointed as lead plaintiff.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged securities fraud. Investors who purchased shares between April 22, 2025, and February 9, 2026, are encouraged to contact the firm before June 5, 2026, to discuss their rights. The complaint alleges that Medpace made false and misleading statements, artificially inflating its share price, and investors suffered damages when the truth became known.
ROSEN, A LONGSTANDING LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
Rosen Law Firm is reminding investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, about the June 8, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements about its backlog cancellation rates, leading to investor damages. The firm encourages affected investors to secure counsel and join the class action to potentially recover losses.
INVESTOR ALERT: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, RGRD Law Announces - MEDP
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP), inviting investors who suffered substantial losses between April 22, 2025, and February 9, 2026, to seek lead plaintiff status. The lawsuit alleges that Medpace made false or misleading statements regarding its projected book-to-bill ratio and the impact of cancellations, specifically concerning its Q4 2025 financial performance. Investors have until June 8, 2026, to apply for lead plaintiff appointment.
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for Medpace Holdings, Inc. (MEDP) shareholders who incurred losses between April 22, 2025, and February 9, 2026. The firm reminds investors of the June 8, 2026, deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its financial prospects, specifically concerning its book-to-bill ratio and reasons for a significant stock price drop on February 10, 2026.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Concealed Cancellation Rate Risks: SueWallSt
A securities class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ: MEDP) on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace management misled investors by repeatedly characterizing backlog cancellation rates as "well behaved" despite worsening trends, leading to a significant stock price drop after Q4 2025 results were disclosed. SueWallSt is alerting investors and providing information on how to participate in the lawsuit, with a lead plaintiff deadline set for June 8, 2026.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Concealed Cancellation Rate Risks: SueWallSt
SueWallSt has issued an investor alert regarding a securities fraud lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP). The class action, filed on behalf of shareholders who purchased securities between April 22, 2025, and February 9, 2026, alleges that Medpace management misled investors by mischaracterizing cancellation rates and the stability of its business environment. The lawsuit claims these misrepresentations led to a significant stock price drop after Q4 2025 results revealed higher-than-anticipated cancellation rates.
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
The Rosen Law Firm is encouraging investors of Medpace Holdings, Inc. (NASDAQ: MEDP) to secure counsel before the June 8, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates between April 22, 2025, and February 9, 2026, leading to investor damages. Investors who purchased Medpace common stock during this period may be entitled to compensation.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Growth Outlook: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP). The lawsuit alleges that Medpace misrepresented its growth outlook, leading to a significant stock drop after its Q4 2025 results revealed a book-to-bill ratio of 1.04x, falling short of the projected 1.15x. Investors who purchased shares between April 22, 2025, and February 9, 2026, and incurred losses are encouraged to contact the firm to potentially lead the class action lawsuit, with a lead plaintiff deadline of June 8, 2026.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Growth Outlook: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP), alleging the company misrepresented its growth outlook and book-to-bill ratio. The firm is seeking investors who purchased shares between April 22, 2025, and February 9, 2026, to potentially lead a class action lawsuit. Investors are encouraged to contact Levi & Korsinsky to evaluate their losses, as the company's stock experienced a significant drop after disclosing a lower-than-projected book-to-bill ratio and increased cancellation rates.
What Are the Core Allegations Against Medpace (MEDP)
Medpace (MEDP) is facing a securities class action lawsuit alleging that its management misled investors about cancellation rates and book-to-bill ratios between April 22, 2025, and February 9, 2026. The lawsuit was filed after Medpace's stock dropped 15.9% on February 10, 2026, following the disclosure of a Q4 2025 book-to-bill ratio of 1.04, which was significantly lower than prior guidance. Investors who suffered losses during this period have until June 8, 2026, to apply for lead plaintiff status in the litigation.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
The Rosen Law Firm is encouraging investors of Medpace Holdings, Inc. (NASDAQ: MEDP) to secure counsel before the June 8, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate and growth expectations between April 22, 2025, and February 9, 2026. Investors who purchased Medpace common stock during this period may be entitled to compensation.
Medpace shareholders approve bylaw changes and board elections at annual meeting
Medpace Holdings, Inc. shareholders recently approved key changes to the company's bylaws, including the removal of supermajority voting requirements and enhanced shareholder ability to call special meetings. They also elected new directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026. This news follows Medpace's Q1 2026 earnings beat, though some analysts have adjusted price targets due to concerns over future growth and cancellation rates.
Medpace (NASDAQ: MEDP) holders approve charter, bylaw changes and pay votes
Medpace Holdings, Inc. shareholders approved significant governance changes at their 2026 annual meeting, including the removal of supermajority voting requirements and limitations on shareholders calling special meetings. The bylaws were amended to allow shareholders owning at least 25% of the voting power for one year to request a special meeting. Additionally, all director nominees were elected, Deloitte & Touche LLP was ratified as auditor, and an annual advisory vote on executive compensation was approved.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings,
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made false and misleading statements regarding its expected book-to-bill ratio, portraying an overly optimistic outlook despite internal information to the contrary. Investors are encouraged to join the case, with a lead plaintiff deadline of June 5, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) alleging that the company and its officers made materially false and misleading statements regarding its expected book-to-bill ratio. The lawsuit covers investors who purchased Medpace securities between April 22, 2025, and February 9, 2026. Investors are urged to join the case, with a lead plaintiff deadline of June 5, 2026.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged violations of securities laws. Investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to contact the firm by June 5, 2026, to potentially lead the lawsuit. The lawsuit alleges that Medpace made false and misleading statements to artificially inflate its share price, leading to investor damages.
MEDP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Medpace Holdings, Inc. Securities Lawsuit - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors in Medpace Holdings, Inc. (NASDAQ: MEDP) who incurred losses between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made misleading statements regarding its backlog cancellation rate, which resulted in a dramatic stock price decline after the company reported a lower-than-guided book-to-bill ratio. Shareholders are encouraged to contact the firm by the June 8, 2026 deadline to potentially serve as lead plaintiff in the class action.
MEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations
Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) and its executives. The lawsuit alleges that Medpace misrepresented its cancellation rates and overstated its book-to-bill ratio, leading to significant stock drops. Investors who suffered losses are encouraged to seek legal counsel, with a lead plaintiff deadline of June 8, 2026.
Medpace (MEDP) director granted 1,110 options at $415.27 per share
Medpace Holdings, Inc. director Robert O. Kraft was granted options to purchase 1,110 shares of common stock at an exercise price of $415.27 per share, expiring on May 15, 2033. This award is a compensation-related grant, not an open-market transaction. Following this grant, Robert O. Kraft directly holds 922 shares of Medpace common stock, and the options will vest subject to his continued service on the board.
MEDP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Medpace Holdings, Inc. Securities Lawsuit - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors in Medpace Holdings, Inc. (NASDAQ: MEDP) announcing a class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates and provided overly positive growth expectations, leading to a significant stock price decline after the company announced a lower-than-projected book-to-bill ratio. Shareholders who purchased MEDP shares between April 22, 2025, and February 9, 2026, are encouraged to contact the firm, with a lead plaintiff deadline of June 8, 2026.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
The Rosen Law Firm is reminding investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, about the June 8, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate and growth expectations. Investors are encouraged to contact the law firm to learn more about joining the class action.
[Form 4] Medpace Holdings, Inc. Insider Trading Activity
Medpace Holdings, Inc. director Femida H. Gwadry-Sridhar was granted stock options for 1,110 shares with an exercise price of $415.27 per share, expiring on May 15, 2033. These options vest on the earlier of the day before the first annual shareholder meeting or the first anniversary of the grant date, provided she remains on the board. Following this transaction, Gwadry-Sridhar directly holds options for 1,110 shares.
[Form 4] Medpace Holdings, Inc. Insider Trading Activity
Medpace Holdings, Inc. director Fred B. Davenport Jr. reported an acquisition of 1,110 stock options on May 15, 2026, allowing him to buy common stock at $415.27 per share, expiring on May 15, 2033. These options will vest on the earlier of the day before the first annual meeting or the first anniversary of the grant, contingent on his continued board service. Following this transaction, Davenport holds 3,498 direct shares and 2,000 indirect shares through a trust.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) alleging securities fraud. The lawsuit claims that Medpace's leadership concealed risks related to backlog deterioration, despite internal knowledge, leading to a significant stock price drop. Investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, and incurred losses, are encouraged to contact the firm to potentially lead the class action.
Northwestern Mutual Wealth Management Co. Purchases 100,968 Shares of Medpace Holdings, Inc. $MEDP
Northwestern Mutual Wealth Management Co. significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, purchasing 100,968 shares to bring their total holdings to 101,373 shares valued at $56.9 million. This increase comes despite a mixed outlook for Medpace, which recently exceeded quarterly earnings expectations but faces a consensus "Hold" rating from analysts and ongoing class-action lawsuit notices impacting sentiment.
Pomerantz LLP Issues Important Reminder to Shareholders in Medpace Holdings, Inc. of Class Action Filing – MEDP
Pomerantz LLP has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) for alleged securities fraud, advising shareholders to contact them to potentially serve as Lead Plaintiff by June 8, 2026. The lawsuit stems from a significant drop in Medpace's stock price following its Q4 2025 earnings report, which revealed a book-to-bill ratio of 1.04, falling short of guidance. Pomerantz LLP, a firm specializing in corporate, securities, and antitrust class litigation, represents victims of securities fraud.
$MEDP Stock News: Medpace Investors Sue For Recovery in Securities Fraud Class Action Over Cancellation Rates
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. for securities fraud. Investors allege Medpace understated cancellation rates and overstated its book-to-bill ratio, leading to significant stock drops. The lawsuit focuses on the company's Q4 2025 financial results and subsequent reports of increased cancellations and the resignation of its President.
Thrivent Financial for Lutherans Has $70.35 Million Holdings in Medpace Holdings, Inc. $MEDP
Thrivent Financial for Lutherans increased its stake in Medpace Holdings, Inc. by 8% in Q4, reaching 125,262 shares valued at $70.35 million. Despite legal challenges from class-action lawsuits alleging investor harm, Medpace reported Q1 earnings that surpassed expectations, with EPS of $4.28 and revenue of $706.6 million. Analysts have largely adopted a "Hold" rating for the stock, with several lowering their price targets.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain officers, alleging federal securities law violations. The lawsuit claims Medpace made materially false and misleading statements about its book-to-bill ratio for Q4 and H2 2025, portraying an overly optimistic ratio despite internal information. Investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of June 5, 2026.
Medpace Holdings, Inc. $MEDP Shares Sold by Bessemer Group Inc.
Bessemer Group Inc. reduced its stake in Medpace Holdings, Inc. by 7.3% in Q4 2025, selling 24,877 shares, though still holding 317,040 shares valued at $178.1 million. Despite beating earnings expectations and raising FY2026 guidance, the stock faces pressure from an ongoing securities-fraud class action and cautious analyst ratings, with a consensus "Hold" and average price target of $467.08. Insiders have also been selling shares, further influencing investor sentiment.
INVESTOR NOTICE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) on behalf of investors who purchased common stock between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made false and misleading statements regarding its projected book-to-bill ratio for Q4 2025, which ultimately fell significantly below guidance, causing a nearly 16% stock drop. Investors with substantial losses have until June 8, 2026, to seek appointment as lead plaintiff.
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders
Glancy Prongay Wolke & Rotter LLP is alerting investors of Medpace Holdings, Inc. (MEDP) about an upcoming June 8, 2026 deadline to file a lead plaintiff motion in a securities fraud class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements between April 22, 2025, and February 9, 2026, regarding its financial projections, specifically its book-to-bill ratio, leading to a significant stock price drop after revealing lower-than-guided results and high backlog cancellations. Investors who suffered losses are urged to contact the firm to inquire about their options.
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Medpace Holdings, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced that a class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ:MEDP) and certain officers. The lawsuit alleges that Medpace made materially false and misleading statements about its book-to-bill ratio. Shareholders who purchased Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to join the lawsuit and have until June 5, 2026, to request to be appointed as lead plaintiff.
Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders
Glancy Prongay Wolke & Rotter LLP warns Medpace Holdings, Inc. (MEDP) shareholders of an upcoming June 8, 2026 deadline to file a lead plaintiff motion in a securities fraud class action lawsuit. The lawsuit alleges that Medpace made misleading statements regarding its book-to-bill ratio and operational prospects, which led to a significant stock price drop after the company reported lower-than-guidance financial results on February 9, 2026. Investors who suffered losses during the Class Period (April 22, 2025, to February 9, 2026) are urged to contact the law firm.
Lost Money on Medpace Holdings, Inc. (MEDP)? Join Class
The Gross Law Firm is notifying shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP) about a class action lawsuit. This suit alleges that Medpace made false and misleading statements about its backlog cancellation rate and growth expectations, leading to a significant stock price decline on February 10, 2026. Shareholders who purchased MEDP shares between April 22, 2025, and February 9, 2026, are encouraged to register and potentially join the action, with a lead plaintiff deadline of June 8, 2026.
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announce a securities fraud class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP). The lawsuit alleges that Medpace made materially misleading statements between April 22, 2025, and February 9, 2026, regarding its projected book-to-bill ratio, the impact of cancellations, and the diversity of its pre-backlog. Investors who suffered losses related to Medpace are encouraged to participate before the lead plaintiff deadline of June 8, 2026.
Medpace Holdings stock (US5840631062): Class action lawsuit announced May 14
Medpace Holdings (NASDAQ:MEDP) is facing a securities class action lawsuit due to alleged misleading statements that artificially inflated its share price between April 2025 and February 2026. Despite recent strong financial results, including significant revenue growth in Q4 CY2025, investors have until June 8, 2026, to seek lead plaintiff status in the ongoing legal scrutiny. The company, a clinical research organization, continues to be a key partner in accelerating new treatment development, with its stock tied to US healthcare R&D trends.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Growth Projections: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP). The lawsuit alleges that Medpace overstated growth projections and misled investors about its book-to-bill ratio and cancellation behavior, leading to a significant stock price drop on February 10, 2026, after Q4 2025 results were disclosed. Investors who suffered losses between April 22, 2025, and February 9, 2026, may seek to lead the class action, with a lead plaintiff deadline of June 8, 2026.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, of the June 8, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rate and growth expectations. Investors are encouraged to contact the law firm to learn more about joining the class action.
A Litigation Wave for Biotech’s Medpace
Medpace Holdings, a significant contract research organization in drug development, is facing securities litigation and increased scrutiny. This comes after a sharp decline in its stock price, concerns over "book-to-bill" ratios and clinical trial cancellations, and the surprise resignation of its president. Sophisticated investors and lawyers, using FOIA requests to the SEC, had begun probing the company before these issues became widely known.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged securities fraud during the period of April 22, 2025, to February 9, 2026. Investors who purchased Medpace securities and suffered losses are encouraged to contact the firm to participate in the lawsuit before the June 5, 2026 deadline. The lawsuit claims Medpace made false and misleading statements, leading to an artificially inflated share price and subsequent investor damages.
ROSEN, A LEADING AND RANKED FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MEDP
Rosen Law Firm is encouraging investors in Medpace Holdings, Inc. (NASDAQ: MEDP) to secure legal counsel before the June 8, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements about its backlog cancellation rates during the Class Period between April 22, 2025, and February 9, 2026. Investors who purchased Medpace common stock during this period may be entitled to compensation.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Growth Projections: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP). The lawsuit alleges that Medpace overstated growth projections and provided misleading information about its book-to-bill ratio and cancellation behavior throughout 2025, leading to a significant stock price drop in February 2026. Investors who suffered losses during the class period (April 22, 2025, to February 9, 2026) are encouraged to seek legal counsel by the lead plaintiff deadline of June 8, 2026.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Certified Misleading Statements: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP), naming senior executives as individual defendants. The lawsuit alleges that Medpace shares fell significantly after corrective disclosures revealed a lower-than-projected book-to-bill ratio, and that the CEO and other officers allegedly certified misleading statements in SEC filings. Investors who suffered losses during the class period (April 22, 2025, through February 9, 2026) are encouraged to seek lead plaintiff appointment by June 8, 2026.
Lost Money on Medpace Holdings, Inc. (MEDP)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP) to join a class action lawsuit. This suit is for investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that Medpace made misleading statements about its backlog cancellation rates and growth expectations. The stock price significantly declined after the company announced a book-to-bill ratio of 1.04, which was below its guidance of 1.15.
Lost Money on Medpace Holdings, Inc. (MEDP)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Medpace Holdings, Inc. (NASDAQ: MEDP) regarding a class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements about its backlog cancellation rate and growth expectations, leading to a significant drop in stock price after the company announced a book-to-bill ratio of 1.04, below its guidance of 1.15. Shareholders who purchased MEDP shares between April 22, 2025, and February 9, 2026, are encouraged to contact the firm by the June 8, 2026 deadline to discuss potential lead plaintiff appointment and recovery.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) and its officers, alleging violations of federal securities laws. The lawsuit claims that Medpace made materially false and misleading statements regarding its expected book-to-bill ratio between April 22, 2025, and February 9, 2026. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of June 5, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain officers, alleging federal securities law violations. The lawsuit claims Medpace made false and misleading statements about its book-to-bill ratio between April 22, 2025, and February 9, 2026. Investors who purchased Medpace securities during this period are encouraged to join the class action, with a lead plaintiff deadline of June 5, 2026.
